HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 74, Issue 1, 2005, Pages 77-86

  Study, Jeffrey J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Erlotinib hydrochloride (HCl); Gefitinib; Glioblastoma multiforme; Mutation; Survival

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CANERTINIB; CARBOPLATIN; CARMUSTINE; CELL SURFACE RECEPTOR; CETUXIMAB; DEXAMETHASONE; DOCETAXEL; ENZYME INDUCING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYBRID PROTEIN; IRINOTECAN; LAPATINIB; LOMUSTINE; MONOCLONAL ANTIBODY; PLACEBO; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 23944495360     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11060-005-0603-7     Document Type: Review

References (91)

1. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States, 2002
2. P Kleihues PC Burger BW Scheithauer et al. 1993 Histological Typing of Tumours of the Central Nervous System 2nd edn, Springer-Verlag Berlin
3. MD Prados V Levin 2000 Biology and treatment of malignant glioma Semin Oncol 27: Suppl 6 1-10
4. HS Friedman T Kerby H Calvert 2000 Temozolomide and treatment of malignant glioma Clin Cancer Res 6: 2585-2597 10914698
5. DR Macdonald 2001 Temozolomide for recurrent high-grade glioma Semin Oncol 28 3-12 10.1053/sonc.2001.26648
6. R Stupp WP Mason MJ Bent Van Den et al. 2004 Concomitant and adjuvant temozolomide (TMZ) and radiotherapy for newly diagnosed glioblastoma multiforme (GBM) Conclusive results of a randomized phase III trials by the EORTC brain and RT groups and NCIC clinical trials group. Proc Am Soc Clin Oncol 23 1(abstract 2)
7. DC Shrieve E Alexander III PM Black et al. 1999 Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome J Neurosurg 90 72-77 10413158
8. HA Fine KBG Dear JS Loeffler et al. 1993 Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585-2597 8453582
9. LA Stewart 2002 Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials The Lancet 359 1011-1018 10.1016/S0140-6736(02)08091-1
10. LM DeAngelis 2003 Benefits of adjuvant chemotherapy in high-grade gliomas Semin Oncol 30 15-18
11. M Westphal DC Hilt E Bortley et al. 2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-Oncol 5: 79-88 10.1215/S1522851702000236 12672279
12. H Brem S Piantadosi PC Burger et al. 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. The Lancet 345 1008-1012
13. WK Yung RE Albright J Olson et al. 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83: 588-593 10.1054/bjoc.2000.1316 10944597
14. Levin V, Yung A, Prados M et al.: Phase II study of Temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol: (abstract 1370), 1997
15. BE Lally J Lacy JM Piepmeier et al. 1997 Survival analysis for patients with primary brain tumors treated with temozolomide Proc Am Soc Clin Oncol 22 113(abstract 1370)
16. AA Brandes M Ermani U Basso et al. 2002 Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study Oncology 63 38-41 10.1159/000065718 12187069
17. KA Jaeckle KR Hess A Yung et al. 2003 Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A north american brain tumor consortium study J Clin Oncol 21 2305-2311 10.1200/JCO.2003.12.097 12805331
18. MR Gilbert P Wen F Lieberman et al. 2003 Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A north american brain tumor consortium (NABTC) study Proc Am Soc Clin Oncol 22 113(abstract 410)
19. ET Wong KR Hess MJ Gleason et al. 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572-2578 10561324
20. CL Arteaga 2001 The epidermal growth factor receptor: From mutant oncogene in non human cancers to therapeutic target in human neoplasia J Clin Oncol 19 Suppl 1 32S-40S 11560969
21. HH Sedlacek 2000 Kinase inhibitors in cancer therapy. A look ahead. Drugs 59 435-476
22. A Wells 1999 Molecules in focus. EGFR receptor Int J Biochem Cell Biol 31 637-643 10.1016/S1357-2725(99)00015-1 10404636
23. C Arteaga 2003 Targeting HER1/EGFR: A molecular approach to cancer therapy Sem Oncol 30 (Suppl 7) 3-14 10.1016/S0093-7754(03)00185-4
24. Shepherd FA, Pereira J, Ciuleanu TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A national cancer institute of Canada clinical trials group (NCIC CTG) trial. Presented at Am Soc Clin Oncol: (abstract 7022), 2004
25. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183-232 7612182
26. P Tang PA Steck WK Yung 1997 The autocrine loop of TGF-alpha/EGFR and brain tumors J Neurooncol 35 303-314 10.1023/A:1005824802617 9440027
27. CY Thomas M Chouinard M Cox et al. 2003 Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells Int J Cancer 104 19-27 10.1002/ijc.10880 12532415
28. M Lund-Johansen R Bjerkvig PA Humphrey SH Bigner DD Bigner OD Laerum 1990 Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro Cancer Res 50: 6039-6044 2393868
29. M-E Halatsch E Gehrke F A-Borhani et al. 2002 EGFR but not PDGFR-β expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines Anticancer Res 23 2315-2320
30. N Shinojima K Tada S Shiraishi et al. 2003 Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 6962-6970 14583498
31. A Chakravarti A Chakladar MA Delaney DE Latham JS Loeffler 2002 The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62: 4307-4315 12154034
32. FG Barker ML Simmons SM Chang et al. 2001 EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiation Oncology Biol Phys 2001 51 410-418 10.1016/S0360-3016(01)01609-1
33. CT Chu KD Everiss CJ Wilkstrand et al. 1997 Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII) Biochem J 324 855-861 9210410
34. CJ Wilkstrand LP Hale SK Batra et al. 1995 Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Res 55 3140-3148 7606735
35. DK Moscatello M Holgado-Madruga AK Godwin et al. 1995 Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res 55 5536-5539 7585629
36. R Nishikawa XD Ji RC Harmon et al. 1994 A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 7727-7731 8052651
37. R Nishikawa XD Ji RC Harmon et al. 1994 A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 7727-7731 8052651
38. M Nagane F Coufal H Lin O Bogler WK Cavenee HJ Huang 1996 A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Res 56 5079-5086 8895767
39. Q Wei B Qian L Clarke et al. 2004 Mutant epidermal growth factor receptor (EGFRvIII) potentiates development of gilomas in a transgenic mouse models Proc Am Assoc Cancer Res 45 5085
40. DK Moscatello M Holgado-Madruga DR Emlet et al. 1998 Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor J Biol Chem 273 200-206 10.1074/ jbc.273.1.200 9417065
41. Y Narita M Nagane K Mishima HJ Huang FB Furnari WK Cavenee 2002 Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas Cancer Res 62 6764-6769 12438278
42. SA Prigent M Nagane H Lin et al. 1996 Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway J Biol Chem 271 25639-25645 10.1074/jbc.271.41.25639 8810340
43. M Klingler-Hoffmann P Bukczynska T Tiganis 2003 Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells Int J Cancer 105 331-339 10.1002/ijc.11085 12704666
44. G Choe S Horvath TF Cloughesy et al. 2003 Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer Res 63 2742-2746 12782577
45. M Klingler-Hoffmann MT Fodero-Tavoletti K Mishima et al. 2001 The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor J Biol Chem 276 46313-46318 10.1074/jbc.M106571200 11514572
46. H-JS Huang M Nagane CK Klingbeil et al. 1997 The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling J Biol Chem 272 2927-2935 10.1074/jbc.272.5.2927 9006938
47. Guillamo J-S, Leuraud P, de Bouard S et al.: Anti-proliferative and anti-invasive EGFR amplification dependent and anti-angiogenic EGFR independent activity of ZD1839 ('Iressa') tyrosine kinase inhibitor on human glioblastomas. Proc Am Assoc Cancer Res 44: (abstract 1009), 2003
48. Learn CA, Archer GE, Riggins GJ et al.: Inhibition of cell cycle progression and invasion of cells expressing epidermal growth factor receptor (EGFR) but not mutant EGFR variant III (EGFRvIII) by the specific EGFR tyrosine kinase inhibitor (TKI) gefitinib (Iressa, ZD1839). Proc Am Assoc Cancer Res 44: (abstract 6199), 2003
49. Li B, Chang C-M, Yuan M et al.: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Society for neuro-oncology eighth annual meeting: 291(abstract CB-13), 2003
50. B Stea R Falsey K Kislin et al. 2003 Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa') Cancer Lett 202 43-51 10.1016/j.canlet.2003.07.006 14643025
51. Stea B, Kislin K, Stadheim CR et al.: ZD1839 (Iressa) radiosensitizes glioblastoma multiforme by altering patterns of gene expression in a time dependent manner. Proc Am Assoc Cancer Res 44: (abstract 6018), 2003
52. JD Moyer EG Barbacci KK Iwata et al. 1997 Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 4838-4848 9354447
53. VA Pollack DM Savage DA Baker et al. 1999 Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 739-748 10525095
54. P Chinnaiyan S-M Huang E Armstrong PM Harari 2003 Radiosensitization following EGFR signaling inhibition by erlotonib (Tarceva™) Int J Radiat Oncol Biol Phys 57 2 Suppl S29410.1016/S0360-3016(03)01153-2
55. Carlson BL, Schroeder MA, Mladek AC et al.: Radiosensitization by OSI-774 of serially transplantable human GBM xenografts. Society for neuro-oncology eighth annual Meeting: 321(abstract MO-01), 2003
56. Halatsch M-E, Gehrke E, A-Borhani F et al.: Inverse correlation of epidermal growth factor receptor (EGFR) messenger RNA induction and suppression of in vitro tumorigenicity by OSI-774, an EGFR tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Proc Am Assoc Cancer Res 44: (abstract 4683), 2003
57. JN Rich DA Reardon T Peery et al. 2004 Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 133-142 10.1200/JCO.2004.08.110 14638850
58. MD Prados S Chang E Burton et al. 2003 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma Eur J Cancer Suppls 1 S1410.1016/S1359-6349(03)90067-X (abstract 33)
59. KK Iwata K Provoncha N Gibson 2002 Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) Proc Am Soc Clin Oncol 21 21a(abstract 79)
60. Vogelbaum MA, Goldlust S, Kanner A: The EGFR tyrosine kinase inhibitor Tarceva™ (OSI-774) shows activity against both wild-type and mutant EGFR function. Society for neuro-oncology eighth annual meeting: 309 (abstract ET-47), 2003
61. A Lal CA Glazer HM Martinson et al. 2002 Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion Cancer Res 62 3335-3339 12067969
62. AB Heimberger CA Learn GE Archer et al. 2002 Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 3496-3502 12429640
63. Allen AM, Ethier SP: CI-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern. Proc Am Assoc Cancer Res 44: (abstract 4683), 2003
64. JL Eller SL Longo DJ Hicklin et al. 2002 Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme Neurosurgery 51 1005-1013 10.1097/00006123-200210000-00028
65. TG Johns E Stockert G Ritter et al. 2002 Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene Int J Cancer 98 398-408 10.1002/ijc.10189 11920591
66. S Takasu T Takahashi S Okamoto et al. 2003 Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor J Neurooncol 63 247-256 10.1023/A:1024320516341 12892230
67. KA Cohen T Liu R Bissonette et al. 2003 DAB389EGF fusion protein therapy of refractory glioblastoma multiforme Curr Pharm Biotechnol 4 39-49 10.2174/1389201033378039 12570681
68. A Yung Vredenburgh T Cloughesy et al. 2004 Erlotinib HCl for glioblastoma multiforme in first relapse, a phase II trial Proc Am Soc Clin Oncol 23 120(abstract 1555)
69. MA Vogelbaum D Peereboom G Stevens et al. 2004 Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: Interim results Proc Am Soc Clin Oncol 23 121(abstract 1558)
70. JJ Raizer LE Abrey P Wen et al. 2004 A phase II trial of erlotinib (OSI-774) in patients (Pts) with recurrent malignant gliomas (MG) not on EIAEDs Proc Am Soc Clin Oncol 23 107(abstract 1502)
71. JH Uhm KV Ballman C Giannini et al. 2004 Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma Proc Am Soc Clin Oncol 23 108(abstract 1505)
72. FS Lieberman T Cloughesy H Fine et al. 2004 NABTC phase I-II study of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas Proc Am Soc Clin Oncol 23 109(abstract 1510)
73. A Chakravarti W Seiferheld HI Robins et al. 2004 An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib + radiation for newly-diagnosed glioblastoma (GBM) patients Proc Am Soc Clin Oncol 23 124(abstract 1571)
74. M Prados W Yung P Wen et al. 2004 Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the north american brain tumor consortium. Proc Am Soc Clin Oncol 23 108(abstract 1504)
75. ET Wong KR Hess MJ Gleason et al. 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572-2578 10561324
76. GM Clark R Perez-Soler L Siu et al. 2003 Rash severity is predictive of increased survival with erlotinib HCl Proc Am Soc Clin Oncol 22 196(abstract 786)
77. L Saltz M Kies JL Abbruzzese et al. 2003 The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies Proc Am Soc Clin Oncol 22 204(abstract 817)
78. J Albanell F Rojo S Averbuch et al. 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 110-124 10.1200/JCO.20.1.110 11773160
79. SN Malik LL Siu EK Rowinsky et al. 2003 Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 9 2478-2486 12855621
80. N Finkler A Gordon M Crozier et al. 2001 Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma Proc Am Soc Clin Oncol 20 208a(abstract 831)
81. GN Hortobagyi G Sauter 2003 Challenges and opportunities for erlotinib (Tarceva): What does the future hold? Semin Oncol 30 Suppl 7 47-53 10.1016/S0093-7754(03)00188-X
82. L Frederick X-Y Wang G Eley et al. 2000 Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res 60 1383-1387 10728703
83. W Pao v Miller M Zakowski et al. 2004 EGFR receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306-13311 10.1073/pnas.0405220101 15329413
84. TJ Lynch DW Bell R Sordella et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 2129-2139 10.1056/NEJMoa040938 15118073
85. JG Paez PA Janne JC Lee et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500 10.1126/science.1099314 15118125
86. PS Mischel R Shai T Shi et al. 2003 Identification of molecular subtypes of glioblastoma by gene expression profiling Oncogene 22 2361-2373 10.1038/sj.onc.1206344 12700671
87. AM Stark P Witzel RJ Strege HH Hugo HM Mehdorn 2003 p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme J Neurol Neurosurg Psychiatry 74 779-783 10.1136/jnnp.74.6.779 12754350
88. G Lammering K Valerie P-S Lin et al. 2001 Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor Clin Cancer Res 7 682-690 11297265
89. G Bowers D Reardon T Hewitt et al. 2001 The relative role of ErbB1-4 receptor kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 1388-1397 10.1038/sj.onc.1204255 11313882
90. IB Weinstein 2002 Addiction to oncogenes - the achilles heal of cancer Science 297 63-64 10.1126/science.1073096 12098689
91. Q-W Fan KM Specht C Zhang DD Goldenberg KM Shokat WA Weiss 2003 Combinatorial efficacy achieved through two-point blockade within a signaling pathway - a chemical genetic approach Cancer Res 63 8930-8938 14695210